Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide, liraglutide) do not increase the risk of thyroid or pancreatic cancer in humans, despite animal model concerns.
If you are prescribed a GLP-1 agonist like semaglutide or liraglutide, you do not need to worry about an increased risk of thyroid or pancreatic cancer based on current human data. The FDA warning is based on animal studies, and large human trials have not confirmed this risk.
GoodRefutesHIGH confidence
Evidence suggests that the risk of pancreatic and thyroid cancer, and overall neoplasias are not increased in patients using GLP-1 receptor agonists.
Why this rating
Based on meta-analyses of RCTs and real-world studies.
Source
Weight-centric prevention of cancer
Diego Añazco et al. · Obesity Pillars · 2024
DOI 10.1016/j.obpill.2024.100106
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intentional weight loss achieved through lifestyle interventions, antiobesity medications, or bariatric surgery reduces the incidence of obesity-associated cancers, particularly hormone-dependent malignancies in postmenopausal women.Good
- Bariatric surgery reduces the overall incidence and mortality of cancer, with a more pronounced effect in women than men.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →